The PDUFA date on May 31, 2026 is the primary catalyst. Monitor FDA decision closely; approval could trigger a significant re-rating, while a CRL would pressure the stock. The extended cash runway reduces near-term dilution risk.
Price Chart
Executive Summary
Cingulate reported a net loss of $9.3M for Q1 2026, widening from $3.9M a year ago, driven by a surge in G&A expenses to $5.7M as it builds commercial infrastructure ahead of a potential CTx-1301 launch. Cash and equivalents rose to $25.9M, extending the runway into 2027, while the PDUFA date for CTx-1301 is May 31, 2026.
Key Financial Metrics
Key Facts
- Net loss of $9.3M for Q1 2026 vs $3.9M in Q1 2025.
- Cash and cash equivalents increased to $25.9M from $10.95M at year-end 2025.
- Working capital improved to $17.0M from $1.7M.
- R&D expenses decreased 1.8% to $2.2M.
- G&A expenses surged to $5.7M from $1.5M due to commercial build-out.
- PDUFA target action date for CTx-1301 is May 31, 2026.
- Closed a $12.0M private placement in February 2026.
Financial Impact
Net loss widened by $5.4M YoY; cash position strengthened by $14.9M.
Risk Factors
- FDA non-approval or Complete Response Letter for CTx-1301.
- Commercial launch costs may continue to pressure cash burn.
- Widening net loss trajectory without approved product revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294884 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 2, 2026 20w ago | 8-K | $0.0601 $0.0114 | ▲ +81.03% | ▲ +82.15% | — |
May 19, 2026 22w ago | 8-K | $0.0601 $0.007200 | ▼ −88.02% | ▼ −93.02% | — |
May 14, 2026 23w ago | 8-K | $0.0601 $0.007200 | ▼ −88.02% | ▼ −91.61% | — |
May 14, 2026 23w ago | Press Release | $0.0601 $0.007200 | ▼ −88.02% | ▼ −91.61% | — |
Apr 27, 2026 26w ago | EFFECT | $0.0601 $0.0189 | ▲ +68.55% | ▲ +73.33% | — |
Mar 18, 2026 31w ago | Press Release | $0.0601 $0.0601 | · 0.00% | ▼ −11.53% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers